Department of Surgery, Hammurabi College of medicine, University of Babylon, Al-Hillah, Babylon, Iraq.
International Journal of Science and Research Archive, 2026, 19(01), 478-486
Article DOI: 10.30574/ijsra.2026.19.1.0730
Received on 01 March 2026; revised on 09 April 2026; accepted on 11 April 2026
In this study, (76) cases of confirmed COVID-19 patients were included, of them, (38) severe cases and (38) non severe cases. There were many demographic data included in the present study includes; age, sex, geographic distribution, ABO system, vaccine. All of 76 cases of COVID-19 subjected to detection of ELISA FOXP3 concentration. Out of 38 cases of severe COVID-19, there were 23(30.3%) male and 15(19.8%) female. Out of 38 cases of non-severe COVID-19, there were 24(31.6%) male and 14(18.4%) female. The cases of COVID-19 categorized according to age(years) into 4 categories from 18 to 96 years, and the results show 35(46%) of the non-severe case in 18-40 years, while most severe cases in 41-96 years. The cases of COVID-19 categorized according to geographic distribution into 2 categories Village areas and Urban areas, the results show 29(38.8) of the non-severe case in Urban areas, while most severe cases in Village areas. The cases of COVID-19 categorized according to vaccine into 2 categories vaccinated and non-vaccinated, the results show 23(30.2%) of the non-severe case in Vaccinated, while most severe cases in Non-Vaccinated.
COVID-19; FOXP3; Regulatory T-cell; Immune system
Preview Article PDF
Muthanna Saleem Abdulameer. Foxp3 serum level in patients with severe nasal and respiratory symptoms due to COVID-19 infection. International Journal of Science and Research Archive, 2026, 19(01), 478-486. Article DOI: https://doi.org/10.30574/ijsra.2026.19.1.0730.






